CD Recombinant Proteins
CD (Cluster of Differentiation) recombinant proteins are engineered forms of cell surface markers found on immune and other cell types. These proteins are essential for cell signaling, adhesion, immune responses, and intercellular communication. Recombinant CD proteins are extensively used in immunology, oncology, vaccine development, and therapeutic research.
Content on CD Recombinant Proteins
- Structure and Function
- CD molecules are diverse in structure and function:
- Receptors (e.g., CD4, CD8): Facilitate immune cell activation and signaling.
- Ligands (e.g., CD40L): Engage receptors to modulate immune responses.
- Adhesion Molecules (e.g., CD11a, CD62L): Mediate cell-cell and cell-matrix interactions.
- Function in:
- T cell activation and differentiation.
- Antigen presentation.
- Regulation of immune and inflammatory responses.
- CD molecules are diverse in structure and function:
Applications of CD Recombinant Proteins
- Immunology Research
- Study the roles of CD molecules in T cell activation, B cell maturation, and antigen presentation.
- Investigate the function of immune checkpoint molecules (e.g., CD28, CTLA-4, PD-1).
- Cancer Research
- Explore CD proteins as targets for cancer immunotherapy, such as CAR-T cell therapies targeting CD19 or CD20.
- Study the tumor microenvironment and immune evasion mechanisms involving CD markers.
- Vaccine Development
- Use recombinant CD molecules to enhance immune responses in vaccine formulations.
- Study the role of CD ligands and receptors in T cell priming and memory formation.
- Diagnostics Development
- Use CD proteins as markers in flow cytometry, immunohistochemistry, or diagnostic assays for disease identification and staging.
- Develop assays to quantify soluble CD molecules as biomarkers for immune activity.
CD recombinant proteins are indispensable tools for advancing research in immunology, oncology, and therapeutic development, providing key insights into immune regulation and cellular interactions.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|